Novocure's Topline Data From Phase 3 TRIDENT Trial Of Tumor Treating Fields Therapy For Newly Diagnosed Glioblastoma Did Not Demonstrate Statistically Significant Improvement In Primary Endpoint Of Overall Survival

뉴스 본문을 불러오고 있어요.

Novocure's Topline Data From Phase 3 TRIDENT Trial Of Tumor Treating Fields Therapy For Newly Diagnosed Glioblastoma Did Not Demonstrate Statistically Significant Improvement In Primary Endpoint Of Overall Survival | 웨이프 WAPE

Novocure's Topline Data From Phase 3 TRIDENT Trial Of Tumor Treating Fields Therapy For Newly Diagnosed Glioblastoma Did Not Demonstrate Statistically Significant Improvement In Primary Endpoint Of Overall Survival

기사 요약

관련 종목

댓글 —